At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 590 enrolled
Drug / intervention
Centanafadine SR +2 moredrug
Likely dose
Centanafadine SR 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Jul 30, 2018·Updated Oct 18, 2021
In Brief
A Phase 3 clinical trial evaluating Centanafadine SR and Placebo for Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder. Completed, enrolled 590 participants across 1 site.
Detailed Summary
This study evaluated the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with ADHD. Participants either received a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartJan 2019
Primary CompletionMay 2020
TodayJul 2026
First PostedJul 30, 2018
Enrollment StartJan 16, 2019
Primary CompletionMay 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.9 years ago
Interventions
Centanafadine SRdrug
100 mg, BID, oral tablets
Placeboother
BID, oral tablet
Centanafadine SRdrug
200 mg, BID, oral tablets